Filing summary
Entity and period: The supplied filing is Ecology Coatings, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2012, not an ABVC Biopharma, Inc. filing. It covers the three and six months ended March 31, 2012; balance-sheet comparisons are to September 30, 2011.
Business context
Ecology Coatings develops ultraviolet-curable coatings for manufacturing markets including electronics, automotive and trucking, paper products, and OEMs. The company reported minimal product revenue and relied on preferred-stock sales and debt to fund operations.
Key financial metrics
| Metric | Three months ended March 31, 2012 | Six months ended March 31, 2012 |
|---|---|---|
| Revenue | $3,665 | $5,714 |
| Operating loss | $330,553 | $789,531 |
| Net income (loss) | $(342,840) | $(619,980) |
| Net loss available to common shareholders | $(529,737) | $(998,669) |
| Basic and diluted loss per share | $(0.03) | $(0.06) |
For the six months, operating cash used was $584,091 and investing cash used was $17,654; financing provided $529,961, including $515,000 from convertible preferred stock. Cash fell from $71,784 at September 30, 2011 to zero at March 31, 2012. No meaningful positive margin is evident given the very small revenue base and substantial operating expenses.
At March 31, current assets were $21,831 versus current liabilities of $1,674,725; total assets were $290,563 and stockholders’ deficit was $1,384,162. Current liabilities included a $604,330 judgment payable, $856,685 in related-party notes payable, and $112,430 of interest payable. A $600,000 secured note to a director is secured by the company’s intellectual property and due December 4, 2012. The company also disclosed approximately $243,500 of short-term debt principal and $57,724 accrued interest in default.
Changes versus prior comparable periods
- Six-month revenue increased to $5,714 from $3,190; quarterly revenue increased to $3,665 from $720. Revenue remained concentrated in three customers in 2012.
- The six-month result shifted from net income of $58,793 in 2011 to a net loss of $619,980 in 2012. The prior-year period included $872,861 of income from forgiveness of payables and debt, compared with $228,802 in 2012.
- Six-month operating loss widened by approximately $93,000, while interest expense declined to $59,251 from $117,941, reflecting lower average debt and replacement of high-interest notes with a judgment bearing a lower stated interest rate.
- Common shares outstanding rose to 16,331,882 from 14,158,506 at September 30, 2011. The filing also reports 41.4 million potentially dilutive shares outstanding, excluded from diluted EPS as anti-dilutive.
Outlook, risks, and unusual items
- Management said additional funding was required by June 2012 to continue operations; absent funding, the company could curtail operations or seek bankruptcy protection. The filing states that only $50,000 remained available under the Fairmount Five financing after May 1, 2012. Subsequent to quarter-end, the company disclosed $90,000 of additional Series C preferred-stock sales in April.
- The financial statements and the company’s prior audit report cite substantial doubt about its ability to continue as a going concern. Future operations depend on financing, revenue growth, product commercialization, and development of profitable operations.
- In December 2011, a court entered a $604,330 judgment for Mitchell Shaheen on defaulted notes; the company said it had not appealed and was discussing satisfaction of the judgment.
- Preferred-stock financing at a $0.06 conversion price and other convertible securities, options, and warrants present substantial dilution risk. The filing reported 35.3 million common shares issuable upon conversion of preferred shares.
- Management reported ineffective disclosure controls due to lack of segregation of financial-reporting duties in its small finance staff. The filing also identifies commercialization, competition, limited manufacturing and marketing capacity, supplier dependence, intellectual-property protection, and key-personnel risks.
- Related-party matters include the director’s secured note, equipment sale-and-leaseback with a chairman-owned entity, and a headquarters lease with that entity effective May 1, 2012.
Important facts to verify
- Confirm the issuer identity: the source filing is for Ecology Coatings, Inc., whereas the request names ABVC Biopharma, Inc.
- Reconcile the accumulated-deficit figures: the balance sheet reports $(29,773,067), while Note 8 gives different figures for the deficit at March 31, 2012 and September 30, 2011.
- Reconcile operating cash used: the cash-flow statement reports $584,091, while MD&A cites $582,315.
- Verify the company’s subsequent financing, liquidity, and ability to meet the June 2012 funding need; the filing provides no later outcome.
- Review the Shaheen judgment, other defaulted obligations, preferred-stock conversion terms, and potential dilution.